Myanmar Pharmaceuticals and Healthcare Report Q2 2014

Myanmar Pharmaceuticals and Healthcare Report Q2 2014


March 5, 2014
53 Pages - SKU: BMI5213904
License type:
Report with 3 quarterly updates      US $1,295.00
Report with 3 quarterly updates - 3 User License      US $1,945.00
Report with 3 quarterly updates - 5 User License      US $2,500.00
Report with 3 quarterly updates - Departmental/Site License      US $2,995.00
Global Site License Fulfilled by Publisher      US $6,995.00
Countries covered: Myanmar

Myanmar Pharmaceuticals and Healthcare Report Q2 2014

BMI View: Commercial opportunities in Myanmar's healthcare sector are largely derived from its largeunmet medical needs and underinvestment. However, we maintain that significant improvements arerequired if Myanmar is to realise its ambitious public health insurance scheme. Political uncertainties dueto the upcoming election in 2015 may also deter investors in the short term.

Headline Expenditure Projections

Pharmaceuticals: MMK324.8bn (US$350mn) in 2013 to MMK387.5bn (US$390mn) in 2014; +19.3%in local currency terms and +11.3% in US dollar terms. Forecast upgraded due to strong growth inpharmaceutical imports.

Healthcare: MMK1,090.7bn (US$1.2bn) in 2013 to MMK1,203.1bn (US$1.2bn) in 2014; +10.3% inlocal currency terms and +2.9% in US dollar terms.



More Prescription Drugs reports by Business Monitor International

Vietnam Pharmaceuticals and Healthcare Report Q2 2014 by Business Monitor International
Vietnam Pharmaceuticals and Healthcare Report Q2 2014BMI View: Vietnam's reliance on imported drugs (both generic and patented) will continue toprovide ample commercial opportunities for foreign ...
United Arab Emirates Pharmaceuticals and Healthcare Report Q2 2014 by Business Monitor International
United Arab Emirates Pharmaceuticals and Healthcare Report Q2 2014BMI View: UAE's increasing investment from public and private sectors in its healthcare industry is set tobring ...
Ghana Pharmaceuticals and Healthcare Report Q2 2014 by Business Monitor International
Ghana Pharmaceuticals and Healthcare Report Q2 2014BMI View: Although our USD headline forecasts for Ghana in Q2014 have been revised lower, this islargely due to ...
United Kingdom Pharmaceuticals and Healthcare Report Q2 2014 by Business Monitor International
United Kingdom Pharmaceuticals and Healthcare Report Q2 2014BMI View: The UK's health technology assessment and pricing/reimbursement decision making bodies arelooking to take an increasingly hard ...
See all reports like this >>

More Myanmar reports

D&B Country RiskLine Report: Myanmar by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
See all reports like this >>